We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS Reports New Phase 3 Results for Psoriasis Treatment
BMS Reports New Phase 3 Results for Psoriasis Treatment
Bristol Myers Squibb (BMS) has reported positive findings from two late-stage clinical trials of deucravacitinib, its experimental treatment for moderate-to-severe plaque psoriasis.